A Randomized Trial of Progesterone in Women with Recurrent Miscarriages


BACKGROUND

Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain.

METHODS

We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twice-daily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation.

RESULTS

A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progesterone group and 63.3% (271 of 428 women) in the placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95% CI, −4.0 to 9.0). There were no significant between-group differences in the rate of adverse events.

CONCLUSIONS

Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages. (Funded by the United Kingdom National Institute of Health Research; PROMISE Current Controlled Trials number, ISRCTN92644181.)
RECURRENT MISCARRIAGE, DEFINED AS the loss of three or more pregnancies, affects approximately 1% of couples who attempt to have a child.1 Even after comprehensive investigations, a cause for recurrent miscarriage is identified in less than half of these couples.1,2 Unexplained recurrent miscarriage is associated with substantial adverse clinical and psychological consequences for the women and their families. Various therapeutic strategies to increase the rate of live births among these women have been evaluated, but no effective treatment has been identified.

Progesterone is essential to achieve and maintain a healthy pregnancy. It is secreted naturally by the corpus luteum during the second half of the menstrual cycle and by the corpus luteum and placenta during early pregnancy. Progesterone prepares the endometrium for implantation of the embryo. If implantation occurs, the corpus luteum continues to produce progesterone, but between 8 and 12 weeks of gestation, the placenta takes over this role and maintains the pregnancy thereafter.3

The physiological importance of progesterone in early pregnancy has prompted the performance of several trials to evaluate the effect of progesterone supplementation in the first trimester of pregnancy among women with a history of recurrent miscarriages. A Cochrane review of four small trials showed a significantly lower risk of miscarriages among women who received progesterone than among those who received placebo or no treatment (odds ratio, 0.39; 95% confidence interval [CI], 0.21 to 0.72), but the quality of the four trials was considered to be poor.4 We designed this multicenter, randomized, placebo-controlled trial (Progesterone in Recurrent Miscarriages [PROMISE]) to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage.

METHODS

STUDY OVERSIGHT
The PROMISE trial was approved by the United Kingdom Medicines and Healthcare Products Regulatory Authority, the National Research Ethics Service, and the research and development department at each participating hospital. Progesterone and placebo were manufactured and supplied by Besins Healthcare. This company had no role in the design of the study; the collection, analysis, or interpretation of the data; or the writing of the report. All the authors were involved in the collection, analysis, and interpretation of the data; the writing and critical review of the manuscript; and the decision to submit the manuscript for publication. Study oversight and monitoring were provided by a trial steering committee and by an independent data and safety monitoring committee. The first, second, and last authors vouch for the accuracy of the data and analyses and for the fidelity of the study to the protocol (available with the full text of this article at NEJM.org).

STUDY PARTICIPANTS
The participants in the PROMISE trial were recruited from hospitals located across the United Kingdom (36 sites) and in the Netherlands (9 sites). Women were eligible for enrollment in the study if they were 18 to 39 years of age and were actively trying to conceive naturally after having received a diagnosis of unexplained recurrent miscarriage (defined as three or more consecutive or nonconsecutive losses of pregnancy in the first trimester). Age criteria were applied for participation in the trial because the likelihood of miscarriages due to random chromosomal aberrations increases with advancing age;1,5 and progesterone therapy would probably not prevent such miscarriages.

All participants gave written informed consent. Participants were excluded from randomization if they were unable to conceive naturally within 1 year after recruitment; had the antiphospholipid syndrome or other recognized thrombophilic conditions; had uterine cavity abnormalities (as assessed with the use of ultrasonography, hysterosonography, hysterosalpingogram, or hysteroscopy), an abnormal parental karyotype, or other identifiable cause of recurrent miscarriage such as diabetes, thyroid disease, or systemic lupus erythematosus (tests were initiated only if clinically indicated); were currently receiving heparin therapy; or had contraindications to progesterone use.

STUDY DESIGN AND DRUG REGIMEN
Participants were randomly assigned in a 1:1 ratio to receive vaginal suppositories containing either 400 mg of micronized progesterone (Utrogestan, Besins Healthcare) twice daily or matched pla-
cebo from a time soon after receiving positive results on a urinary pregnancy test (and no later than 6 weeks of gestation) through 12 completed weeks of gestation (or earlier if an ectopic pregnancy was diagnosed or miscarriage occurred before 12 weeks). Computerized randomization was performed centrally through a secure Internet facility with the use of minimization to balance the study-group assignments according to the number of previous miscarriages (3 or ≥4), maternal age (≤35 or >35 years), presence or absence of polycystic ovaries, and body-mass index (BMI [the weight in kilograms divided by the square of the height in meters], ≤30 or >30).

The appearance, route, and timing of administration of the study drugs were identical in the placebo and progesterone groups. Participants, physicians, and trial nurses were unaware of the study-group assignments throughout the trial.

**OUTCOME MEASURES**

The primary outcome measure was live birth after 24 completed weeks of gestation. Secondary outcomes included clinical pregnancy (presence of at least a gestational sac) at 6 to 8 weeks, ongoing pregnancy with fetal heart activity at 12 weeks, miscarriage (pregnancy loss before 24 weeks of gestation), the week of gestation at delivery, survival at 28 days of neonatal life, and congenital abnormalities (specifically genital anomalies, because there has been concern about a possible increased risk of hypospadias with the use of certain progesterone analogues6). Exploratory outcomes included obstetrical conditions such as preeclampsia, small size for gestational age (<10th percentile for birth weight), preterm pre-labor rupture of membranes, antepartum hemorrhage, and mode of delivery, as well as neonatal variables such as birth weight, arterial and venous pH, Apgar scores, and need for ventilation support.

**STATISTICAL ANALYSIS**

We calculated that we would need to assign 376 women to each study group for the study to have 80% power to detect a minimally important absolute difference of 10 percentage points between the progesterone group and the placebo group with respect to the rate of live births after 24 weeks (from 60% to 70%; odds ratio, 1.56), at an alpha level of 0.05. We planned to include 790 women in the study to account for a 5% rate of loss to follow-up. Categorical baseline data were reported as absolute numbers and percentages. Normally distributed continuous variables were summarized as means with standard deviations, and nonnormally distributed continuous variables were reported as medians with interquartile ranges. The analyses were performed according to the intention-to-treat principle. Binary regression with a log-link function was used to determine the relative rates for the primary outcome and other binary outcomes, with adjustment for the minimization variables. Continuous outcomes were analyzed as mean differences or ratios, as appropriate.

The primary end point was analyzed with the use of multivariate logistic regression in three prespecified subgroups defined according to maternal age (≤35 vs. >35 years), number of previous miscarriages (3 vs. ≥4), and presence or absence of polycystic ovaries, and in three additional post hoc subgroups defined according to gestation at treatment start (<5 weeks 0 days vs. ≥5 weeks 0 days), BMI (≤30 vs. >30), and country (United Kingdom vs. the Netherlands). In each subgroup analysis, we first used a chi-square test for interaction to determine whether the effects of progesterone and placebo differed in any of the subgroups.

Interim analyses of principal safety and effectiveness end points were performed on behalf of the data and safety monitoring committee on two occasions. Because these analyses were performed with the use of the Peto principle,2 no adjustment was made in the final P values to determine significance.

**RESULTS**

**STUDY PARTICIPANTS**

A total of 1568 women were assessed for eligibility for the PROMISE trial from June 23, 2010, through October 23, 2013, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women) (Fig. 1). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). The baseline characteristics were similar in the two study groups (Table 1).

**OUTCOMES**

The rate of live births after 24 weeks of gestation was 65.8% (262 of 398 pregnancies) in the prog-
The new england journal of medicine

Gestosterone group, as compared with 63.3% (271 of 428 pregnancies) in the placebo group (relative rate, 1.04; 95% CI, 0.94 to 1.15; absolute rate difference, 2.5 percentage points; 95% CI, −4.0 to 9.0).

There were no significant between-group differences in the rates of clinical pregnancy (at 6 to 8 weeks), ongoing pregnancy (at 12 weeks), ectopic pregnancy, miscarriage, stillbirth, and neonatal outcomes, as well as in the median gestational age at miscarriage (Table 2). A total of 533 pregnancies in the two study groups progressed to live birth after 24 weeks; the babies were delivered before 34 weeks in 10 of 262 pregnancies (3.8%) in the progesterone group.
and in 10 of 271 pregnancies (3.7%) in the placebo group (relative risk, 1.03; 95% CI, 0.44 to 2.45). The distributions of gestational age at the time of live-birth delivery were similar in the two study groups (Fig. 2). The frequency of adverse events did not differ

### Table 1. Characteristics of the Participants at Baseline.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Progesterone (N=404)</th>
<th>Placebo (N=432)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age — yr†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>32.9</td>
<td>32.5</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>29.3–36.3</td>
<td>28.9–35.9</td>
</tr>
<tr>
<td>Maternal BMI</td>
<td>25.5±5.1</td>
<td>25.3±5.1</td>
</tr>
<tr>
<td>Maternal BMI &gt;30.0 — no./total no. (%)</td>
<td>63/404 (15.6)</td>
<td>65/432 (15.0)</td>
</tr>
<tr>
<td>Maternal race — no./total no. (‡)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>316/399 (79.2)</td>
<td>366/424 (86.3)</td>
</tr>
<tr>
<td>Black</td>
<td>16/399 (4.0)</td>
<td>19/424 (4.5)</td>
</tr>
<tr>
<td>Asian</td>
<td>39/399 (9.8)</td>
<td>29/424 (6.8)</td>
</tr>
<tr>
<td>Other, including mixed race</td>
<td>28/399 (7.0)</td>
<td>10/424 (2.4)</td>
</tr>
<tr>
<td>Maternal smoking — no./total no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsmoker</td>
<td>339/404 (83.9)</td>
<td>363/432 (84.0)</td>
</tr>
<tr>
<td>&lt;10 cigarettes/day</td>
<td>28/404 (6.9)</td>
<td>34/432 (7.9)</td>
</tr>
<tr>
<td>≥10 to 19 cigarettes/day</td>
<td>31/404 (7.7)</td>
<td>27/432 (6.2)</td>
</tr>
<tr>
<td>≥20 cigarettes/day</td>
<td>6/404 (1.5)</td>
<td>8/432 (1.9)</td>
</tr>
<tr>
<td>Alcohol use — no./total no. (%)§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>229/404 (56.7)</td>
<td>260/432 (60.2)</td>
</tr>
<tr>
<td>≤3 units/day</td>
<td>92/404 (22.8)</td>
<td>89/432 (20.6)</td>
</tr>
<tr>
<td>&gt;3 to ≤20 units/day</td>
<td>82/404 (20.3)</td>
<td>83/432 (19.2)</td>
</tr>
<tr>
<td>&gt;20 units/day</td>
<td>1/404 (0.2)</td>
<td>0/432</td>
</tr>
<tr>
<td>Parity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous live birth — no./total no. (%)</td>
<td>167/404 (41.3)</td>
<td>179/432 (41.4)</td>
</tr>
<tr>
<td>≥4 previous miscarriages — no./total no. (%)</td>
<td>183/404 (45.3)</td>
<td>192/432 (44.4)</td>
</tr>
<tr>
<td>Previous pregnancy losses — no.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>3.0–5.0</td>
<td>3.0–4.0</td>
</tr>
<tr>
<td>Clinical risk factors — no./total no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polycystic ovaries</td>
<td>30/404 (7.4)</td>
<td>28/432 (6.5)</td>
</tr>
<tr>
<td>Fibroids</td>
<td>15/404 (3.7)</td>
<td>14/432 (3.2)</td>
</tr>
<tr>
<td>Large-loop excision of the cervical transformation zone</td>
<td>10/404 (2.5)</td>
<td>19/432 (4.4)</td>
</tr>
<tr>
<td>Family history of recurrent miscarriages</td>
<td>55/368 (14.9)</td>
<td>63/391 (16.1)</td>
</tr>
<tr>
<td>Concurrent medications — no./total no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>4/404 (1.0)</td>
<td>2/432 (0.5)</td>
</tr>
<tr>
<td>Aspirin</td>
<td>38/404 (9.4)</td>
<td>37/432 (8.6)</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. The baseline data (age, body-mass index [BMI; the weight in kilograms divided by the square of the height in meters], maternal race, smoking status, and parity) of the participants were similar (without significant differences) in the two study groups.

† Listed is the maternal age at the time of randomization.

‡ Race was self-reported.

§ One unit is 10 g of pure alcohol.
significantly between the progesterone group and the placebo group (Table S1 in the Supplementary Appendix, available at NEJM.org). Neonatal congenital anomalies were observed in 3.5% of the babies (8 of 266 babies [3.0%] in the progesterone group, as compared with 11 of 276 babies [4.0%] in the placebo group; relative risk, 0.75; 95% CI, 0.31 to 1.85). A urogenital abnormality was observed in 1 baby in each group (a hypospadias in the progesterone group and a urachal cyst in the placebo group).

No evidence of effect modification was identified in the prespecified subgroups (defined according to maternal age, number of previous miscarriages, and presence or absence of polycystic ovaries) or in the post hoc subgroups (defined according to gestation at the start of treatment, BMI, and country) (Table S2 in the Supplementary Appendix). In exploratory analyses, we found no significant differences between the two study groups in the rates of obstetrical or neonatal adverse outcomes (Table S3 in the Supplementary Appendix).

**Discussion**

This large multicenter, randomized, placebo-controlled trial showed that progesterone therapy in the first trimester of pregnancy did not result in a significant increase in the rate of live births among women with a history of unexplained recurrent miscarriages. Our results do not support earlier findings of a Cochrane analysis that suggested a benefit of progesterone therapy in the first trimester of pregnancy.4 The Cochrane analysis pooled the results from four small trials that had substantive methodologic limitations;8-11 none of the trials specified the method of concealment of study-group assignments, and only two trials used a placebo for comparison. A more recent double-blind, placebo-controlled, randomized trial of oral dydrogesterone (given from the time that pregnancy was confirmed until 20 weeks of gestation) among 360 women with a history of recurrent miscarriages also showed a benefit of progesterone in reducing a subsequent risk of miscarriage.12

### Table 2. Primary Outcome and Secondary Outcomes.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Progesterone</th>
<th>Placebo</th>
<th>Relative Risk (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical pregnancy at 6 to 8 weeks</td>
<td>326/398 (81.9)</td>
<td>334/428 (78.0)</td>
<td>1.05 (0.98–1.12)</td>
<td>0.16</td>
</tr>
<tr>
<td>Ongoing pregnancy at 12 weeks</td>
<td>267/398 (67.1)</td>
<td>277/428 (64.7)</td>
<td>1.04 (0.94–1.14)</td>
<td>0.47</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td>6/398 (1.5)</td>
<td>7/428 (1.6)</td>
<td>0.92 (0.31–2.72)</td>
<td>0.88</td>
</tr>
<tr>
<td>Miscarriage*</td>
<td>128/398 (32.2)</td>
<td>143/428 (33.4)</td>
<td>0.96 (0.79–1.17)</td>
<td>0.70</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>1/398 (0.3)</td>
<td>2/428 (0.5)</td>
<td>0.54 (0.05–5.92)</td>
<td>0.61</td>
</tr>
<tr>
<td>Live birth after 24 weeks 0 days of gestation</td>
<td>262/398 (65.8)</td>
<td>271/428 (63.3)</td>
<td>1.04 (0.94–1.15)</td>
<td>0.45</td>
</tr>
<tr>
<td>Twin live births after 24 weeks 0 days of</td>
<td>4/398 (1.0)</td>
<td>5/428 (1.2)</td>
<td>0.86 (0.23–3.18)</td>
<td>0.82</td>
</tr>
<tr>
<td>gestation†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestation outcomes among women with live births</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Live birth before 28 weeks 0 days of gestation</td>
<td>1/262 (0.4)</td>
<td>1/271 (0.4)</td>
<td>1.03 (0.06–16.49)</td>
<td>0.98</td>
</tr>
<tr>
<td>Live birth before 34 weeks 0 days of gestation</td>
<td>10/262 (3.8)</td>
<td>10/271 (3.7)</td>
<td>1.03 (0.44–2.45)</td>
<td>0.94</td>
</tr>
<tr>
<td>Live birth before 37 weeks 0 days of gestation</td>
<td>27/262 (10.3)</td>
<td>25/271 (9.2)</td>
<td>1.12 (0.67–1.87)</td>
<td>0.68</td>
</tr>
<tr>
<td>Neonatal outcomes‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any congenital anomaly</td>
<td>8/266 (3.0)</td>
<td>11/276 (4.0)</td>
<td>0.75 (0.31–1.85)</td>
<td>0.54</td>
</tr>
<tr>
<td>Genital congenital anomaly</td>
<td>1/266 (0.4)</td>
<td>1/276 (0.4)</td>
<td>1.04 (0.07–16.50)</td>
<td>0.98</td>
</tr>
<tr>
<td>Newborn survival to 28 days†</td>
<td>260/261 (99.6)</td>
<td>269/269 (100)</td>
<td>1.00 (0.99–1.00)</td>
<td>0.32</td>
</tr>
</tbody>
</table>

* The median gestational age at miscarriage was 7.3 weeks (interquartile range, 6.0 to 8.7) in the progesterone group and 7.1 weeks (interquartile range, 6.0 to 8.5) in the placebo group (relative risk, 0.0; 95% CI, −0.6 to 0.4; P = 0.87).
† The end point is listed per trial participant.
‡ The end point is listed per neonate.
lowering the risk of preterm birth.16-18

shown the efficacy of vaginal progesterone in
considered. We studied a vaginal preparation of
this route to deliver a greater proportion of the
drug to the biologically relevant site (i.e., the
uterus),13,14 and the dose used (400 mg twice daily)
represents a dose at the top end of the therapeu-
tic window.15 Some researchers have suggested
that intramuscular preparations of progesterone
may provide greater therapeutic benefit than
vaginal preparations; however, data are lacking
to support this contention, and previous trials of
alternative progesterone preparations (including
intramuscular progesterone) have shown varying
results.8,9 Furthermore, previous studies have
shown the efficacy of vaginal progesterone in
lowering the risk of preterm birth.16-18

We initiated progesterone treatment after
pregnancy was confirmed, and thus our study
cannot address whether progesterone supple-
mentation could be more effective in reducing
the risk of miscarriage if administered during
the luteal phase of the cycle, before the confir-
mation of pregnancy.19-22 We discontinued pro-
gesterone at 12 weeks of gestation but consider
it unlikely that therapy beyond this time would
result in better outcomes; it is well documented
that corpus luteal function is replaced by placent-
al production of progesterone before the end of
the first trimester.3 Moreover, among PROMISE
participants who had a miscarriage, the median
gestation was less than 8 weeks (7.3 weeks in the
progesterone group and 7.1 weeks in the
placebo group).

We found no increase in the risk of congeni-
tal anomalies among offspring of women treated
with progesterone, although the study was not
powered for such rare outcomes. Nonetheless,
this finding is reassuring because progesterone
therapy is commonly used as part of assisted-
conception treatment.

In conclusion, our trial showed no significant
increase in the rate of live births with the use
of vaginal progesterone in the first trimester of
pregnancy among women with recurrent miscar-
riages. Our results do not support the earlier
findings of a Cochrane review4 that suggested a
benefit of progesterone therapy in the first trimes-
ter among women with recurrent miscarriages.

This report presents independent research comissioned
by the National Institute for Health Research (NIHR). A mon-
ograph reporting the data collected in this study will be pub-
lished in the NIHR Journals Library. Further information is
available at www.journalslibrary.nihr.ac.uk/hta. The views and
opinions expressed by authors in this publication are those of
the authors and do not necessarily reflect those of the NHS, the
NIHR, the Medical Research Council, the Central Commission-
ing Facility, the NIHR Evaluation, Trials and Studies Coordinat-
ing Center, the Health Technology Assessment program, or the
Department of Health.

Supported by the United Kingdom NIHR Health Technology
Assessment program (project number HTA 08 38 01).

Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.

We thank all the women who participated in this study; the
following investigators for supervising recruitment and randomi-
zation at the study centers: Dr. Shamma Al-Inizi, Dr. Adjou Appiah,
Dr. Maysone Backos, Mr. Faisal Basama, Mr. Steve Bober, Dr.
Manisha Chandra, Dr. Sangeeta Das, Dr. Edmond Edi-Osagie,
Dr. Isaac Evbuomwan, Dr. Joanna Fuller, Dr. Elizabeth Haslett,
Dr. Shehnaz Jivraj, Dr. Lisa Joels, Dr. Anjali Kalaskar, Mr. Jayaprakasan Kanna, Dr. Walter Kuchenbecker, Dr. Shonag Macken-
zie, Dr. Iona MacLeod, Dr. Padma Manda, Dr. Patricia Merelina,
Dr. Neela Mukhopadhaya, Dr. Nalini Munjuluri, Dr. Denise Per-
quin, Dr. Judith Roberts, Mr. Gamal Sayed, Ms. Gillian Scotten,
Dr. Seema Sen, Mr. Guy Thorpe-Beeston, Dr. Sandra Watson, and
Mr. Simon Wood; all the PROMISE research nurses who assisted
in the collection of data; Dr. Christine Godfrey and Dr. Peter
Braude for providing advice and assistance in the design of
the study; Dr. Siladitya Bhattacharya for chairing the trial steering
committee; Dr. Jennifer Kurinczuk for chairing the data and safe-

Figure 2. Distribution of Gestational Age According to Study Group Assignment.
Only pregnancies that continued beyond 24 weeks are shown. The hazard
to miscarriage in the progesterone group, as compared with the pla-


The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF BIRMINGHAM on November 26, 2015. For personal use only. No other uses without permission. Copyright © 2015 Massachusetts Medical Society. All rights reserved.
ty monitoring committee; Dr. Javier Zamora and Dr. Nick Rainef-Fenning for participating in the data monitoring committee; study pharmacists Ms. Victoria Latham and Ms. Soniya El Yandouzi; service user representative Ms. Liz Campbell; officers of the Royal College of Obstetricians and Gynecologists Women's Network (formerly known as the Royal College of Obstetricians and Gynecologists Consumers' Forum); and all those not otherwise mentioned above who have contributed to the PROMISE study.

APPENDIX


The authors’ affiliations are as follows: the College of Medical and Dental Sciences, University of Birmingham (A.C., H.W., E.T., J.I.C., A. Eapen, M.D.K.), Heart of England NHS Foundation Trust (R.S., P.G.), and Sandwell and West Birmingham Hospitals NHS Teaching Trust (A. Ewies), Birmingham, King’s College London and King’s Health Partners at St. Thomas’ Hospital (P.T.S.), Women’s Health Research Center, Imperial College at St. Mary’s Hospital Campus (R.B., R.C., L.S., L.R., R.R.), King’s Health Partners at St. Thomas’ Hospital (A.L.B.), King’s College Hospital NHS Foundation Trust (J.A.R.), and Assisted Conception Unit, Guy’s and St. Thomas’ Foundation Trust (Y.K.), London, Biomedical Research Unit in Reproductive Health, University of Warwick, Warwick (S.Q.), Liverpool Women’s NHS Foundation Trust (F.D., R.G.F.), Liverpool, The Miscarriage Association, Wakefield (R.B.A.), University of Southampton Faculty of Medicine, Princess Anne Hospital, Southampton (I.C.C.), Royal Hallamshire Hospital, Sheffield (T.-C.L.), Avshir Maternity Unit, University Hospital of Crosshouse, Kilmarnock (M.M.), University Hospitals NHS Trust, Nottingham (J.M.), Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne (J.S.), and Portsmouth Hospitals NHS Trust, Portsmouth (N.V.) — all in the United Kingdom; the Department of Reproductive Medicine, University Medical Center Utrecht, Utrecht (E.Y.M.K.), the Department of Obstetrics, Leiden University Medical Center, Leiden (K.W.M.B.), the Department of Reproductive Medicine and Gynecology, University of Groningen, Groningen (A.H.), the Department of Obstetrics and Gynecology, Onze Lieve Vrouwe Gasthuis (E.M.K.), and Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Academic Medical Center (M.G.), Amsterdam, and the Department of Obstetrics and Gynecology, Maxima Medical Center Veldhoven, Veldhoven (C.A.M.K.) — all in the Netherlands; and the Robinson Institute, School of Pediatrics and Reproductive Health, University of Adelaide, Adelaide, SA, Australia (B.W.M.).

REFERENCES


Copyright © 2015 Massachusetts Medical Society.